INT69486

From wiki-pain
Revision as of 22:43, 20 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.10
First Reported 1997
Last Reported 2010
Negated 0
Speculated 2
Reported most in Body
Documents 34
Total Number 36
Disease Relevance 19.03
Pain Relevance 0.60

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

molecular_function (Bcl2a1c) cellular_component (Bcl2a1c) biological_process (Bcl2a1c)
Anatomy Link Frequency
blood 2
plasma 2
fat 1
brain 1
upper 1
Bcl2a1c (Mus musculus)
Pain Link Frequency Relevance Heat
agonist 35 96.80 Very High Very High Very High
Bile 103 82.24 Quite High
Central nervous system 11 74.48 Quite High
abdominal pain 8 59.36 Quite High
tolerance 117 58.20 Quite High
Neuropeptide 2 46.00 Quite Low
Withdrawal 18 42.56 Quite Low
Headache 8 34.72 Quite Low
Inflammatory marker 8 11.48 Low Low
aspirin 198 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Weight Loss 303 99.72 Very High Very High Very High
Diabetes Mellitus 4939 99.52 Very High Very High Very High
Albuminuria 118 99.28 Very High Very High Very High
Cardiovascular Disease 663 98.92 Very High Very High Very High
Hypoglycemia 763 98.40 Very High Very High Very High
Vomiting 338 97.72 Very High Very High Very High
Diabetes Complications 70 97.48 Very High Very High Very High
Hyperglycemia 402 97.36 Very High Very High Very High
Obesity 140 97.00 Very High Very High Very High
Pressure Volume 2 Under Development 31 96.40 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A1C decreased from 8.1 ± 1.9 to 6.9 ± 1.3% (1.4 ± 1.6%).
Negative_regulation (decreased) of A1C
1) Confidence 0.10 Published 2008 Journal Diabetes Care Section Body Doc Link PMC2551631 Disease Relevance 0.06 Pain Relevance 0
In the pooled analysis, compared with subjects with the Ser/Ser genotype, subjects with the Ala/Ala genotype had a 7.7% greater decrease in FPG (P < 0.001), an 11.9% greater decrease in 2-h plasma glucose (P = 0.003), and a 3.5% greater decrease in A1C (P = 0.06) after 8 weeks of treatment with gliclazide.
Negative_regulation (decrease) of A1C in plasma
2) Confidence 0.10 Published 2008 Journal Diabetes Care Section Abstract Doc Link PMC2551631 Disease Relevance 0.13 Pain Relevance 0.03
Given the powerful risk associations between microalbuminuria and cardiovascular complications in type 2 diabetes and the lack of effective therapy to reduce hyperglycemia without causing hypoglycemia, our data strongly support the aggressive reduction of albuminuria to compensate for our inability to reduce A1C to <6.2% safely.
Negative_regulation (reduce) of A1C associated with hypoglycemia, hyperglycemia, diabetes mellitus and albuminuria
3) Confidence 0.10 Published 2008 Journal Diabetes Care Section Body Doc Link PMC2584184 Disease Relevance 1.31 Pain Relevance 0
The decrease in A1C after 8 weeks of treatment with gliclazide was 3.5% greater in patients with the Ala/Ala genotype than in those with the Ser/Ser genotype (P = 0.06) (Table 3).
Negative_regulation (decrease) of A1C
4) Confidence 0.08 Published 2008 Journal Diabetes Care Section Body Doc Link PMC2551631 Disease Relevance 0 Pain Relevance 0
The associations between quantitative phenotypes (FPG, 2-h plasma glucose, or A1C decrease [percent]) and genotypes were tested using linear regression models.
Negative_regulation (decrease) of A1C in plasma
5) Confidence 0.08 Published 2008 Journal Diabetes Care Section Body Doc Link PMC2551631 Disease Relevance 0.09 Pain Relevance 0
Colesevelam resulted in a significant mean A1C reduction (0.54%) by week 26 in the total population, with the sulfonylurea monotherapy and sulfonylurea combination therapy cohorts reporting a significant reduction at week 26 as well (0.79 and 0.42%, respectively).
Negative_regulation (reduction) of A1C
6) Confidence 0.06 Published 2008 Journal Diabetes Care Section Body Doc Link PMC2494667 Disease Relevance 0.39 Pain Relevance 0
This study showed that colesevelam significantly reduced A1C and LDL cholesterol concentration in patients with type 2 diabetes when added to a sulfonylurea-based therapy.
Negative_regulation (reduced) of A1C associated with diabetes mellitus
7) Confidence 0.05 Published 2008 Journal Diabetes Care Section Body Doc Link PMC2494667 Disease Relevance 0.88 Pain Relevance 0.10
Colesevelam reduced A1C by 0.32 ± 0.066%, whereas placebo increased A1C by 0.23 ± 0.065%, resulting in a significant LS mean treatment difference of ?
Negative_regulation (reduced) of A1C
8) Confidence 0.05 Published 2008 Journal Diabetes Care Section Body Doc Link PMC2494667 Disease Relevance 0 Pain Relevance 0
A significantly greater percentage of subjects in the colesevelam group achieved an A1C reduction ?
Negative_regulation (reduction) of A1C
9) Confidence 0.05 Published 2008 Journal Diabetes Care Section Body Doc Link PMC2494667 Disease Relevance 0 Pain Relevance 0
While the magnitude of A1C reduction may appear modest, it is similar to the observed effect from another study in which a new antidiabetes agent was combined with a sulfonylurea in patients with advanced type 2 diabetes (16).
Negative_regulation (reduction) of A1C associated with diabetes mellitus
10) Confidence 0.05 Published 2008 Journal Diabetes Care Section Body Doc Link PMC2494667 Disease Relevance 0.38 Pain Relevance 0
RESEARCH DESIGN AND METHODS—A 26-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter study was carried out between August 2004 and August 2006 to evaluate the efficacy and safety of colesevelam for reducing A1C in adults with type 2 diabetes whose glycemic control was inadequate (A1C 7.5–9.5%) with existing sulfonylurea monotherapy or sulfonylurea in combination with additional oral antidiabetes agents.
Negative_regulation (reducing) of A1C associated with diabetes mellitus
11) Confidence 0.05 Published 2008 Journal Diabetes Care Section Abstract Doc Link PMC2494667 Disease Relevance 0.50 Pain Relevance 0
A short-term, double-blind, placebo-controlled pilot study in subjects with type 2 diabetes inadequately controlled with metformin and/or sulfonylurea therapy was conducted; after 12 weeks, colesevelam reduced A1C by 0.50% in the total population (P = 0.007 vs. placebo) and by 1.0% in those with a baseline A1C ?
Negative_regulation (reduced) of A1C associated with diabetes mellitus
12) Confidence 0.05 Published 2008 Journal Diabetes Care Section Body Doc Link PMC2494667 Disease Relevance 0.60 Pain Relevance 0.12
This study required 400 randomized subjects and had 86–95% power to detect a difference of a 0.50–0.80% reduction in mean A1C from baseline between colesevelam and placebo (with a two-sided type I error at 0.05), assuming a common SD of ?
Negative_regulation (reduction) of A1C
13) Confidence 0.05 Published 2008 Journal Diabetes Care Section Body Doc Link PMC2494667 Disease Relevance 0 Pain Relevance 0
Hb A1c, the most reliable indicator of long-term glycemic control, decreased over the course of treatment, resulting in a mean decrease of -0.7% (P < 0.001).
Negative_regulation (decreased) of A1c
14) Confidence 0.02 Published 1997 Journal Clin Ther Section Abstract Doc Link 9152567 Disease Relevance 0.84 Pain Relevance 0.06
Although both strategies lead to similar reduction of A1C in patients with type 2 diabetes, it seems reasonable to postulate that GLP-1R agonists and dipeptidyl peptidase-4 inhibitors may produce different effects on brain mechanisms regulating glucose homeostasis and cardiovascular function, an issue that will be important to address in future studies.



Negative_regulation (reduction) of A1C in brain associated with diabetes mellitus and agonist
15) Confidence 0.02 Published 2008 Journal Diabetes Section Body Doc Link PMC2551665 Disease Relevance 0.25 Pain Relevance 0.31
A larger 26-week randomized trial of 322 type 1 diabetic patients showed that adults age 25 years and older using intensive insulin therapy and CGM experienced a 0.5% reduction in A1C (from ?
Negative_regulation (reduction) of A1C associated with diabetes mellitus
16) Confidence 0.01 Published 2010 Journal Diabetes Care Section Body Doc Link PMC2797382 Disease Relevance 0.33 Pain Relevance 0
A meta-analysis of SMBG in non–insulin-treated patients with type 2 diabetes concluded that some regimen of SMBG was associated with a reduction in A1C of 0.4%.
Negative_regulation (reduction) of A1C associated with diabetes mellitus
17) Confidence 0.01 Published 2010 Journal Diabetes Care Section Body Doc Link PMC2797382 Disease Relevance 0.65 Pain Relevance 0
In each of these large randomized prospective clinical trials, treatment regimens that reduced average A1C to 7% (1% above the upper limits of normal) were associated with fewer markers of long-term microvascular complications; however, intensive control was found to increase the risk of severe hypoglycemia and led to weight gain (46,60,62).
Negative_regulation (reduced) of A1C in upper associated with hypoglycemia and weight gain
18) Confidence 0.01 Published 2010 Journal Diabetes Care Section Body Doc Link PMC2797382 Disease Relevance 0.99 Pain Relevance 0
They likely could have greater efficacy if they suggested specific therapeutic interventions to be considered for a particular patient at a particular point in time (404).Availability of case or (preferably) care management services (405): Nurses, pharmacists, and other nonphysician health care professionals using detailed algorithms working under the supervision of physicians have demonstrated the greatest reduction in A1C and blood pressure (406,407).
Negative_regulation (reduction) of A1C in blood
19) Confidence 0.01 Published 2010 Journal Diabetes Care Section Body Doc Link PMC2797382 Disease Relevance 0.14 Pain Relevance 0
In one study, those subjects with type 2 diabetes demonstrated a greater decrease in A1C with a low-carbohydrate diet than with a low-fat diet (103).
Negative_regulation (decrease) of A1C in fat associated with diabetes mellitus
20) Confidence 0.01 Published 2010 Journal Diabetes Care Section Body Doc Link PMC2797382 Disease Relevance 1.11 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox